Pipeline › pemvidutide
pemvidutide
Not FDA-approved, and in phase 2 development, not authorised in the European Union. 2 active trials, the next due to complete 2027-09-30.
GLP-1/glucagon agonist, SC, from Altimmune. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase2
- Target
- GLP-1/glucagon
- Route
- SC
- Sponsor
- Altimmune
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 2 (1 in phase 3)
- Participants enrolled
- 1,921
- Trials with a reporting date
- 2
- Approved FDA submissions
- 0
Recent changes
| Detected | Change | Trial | Detail | Phase |
|---|---|---|---|---|
| 2026-08-31 | New trial registered | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH NCT07795164 · Altimmune, Inc. | Recruiting, n=1,800 | P3 |
When these trials report
Next 2 of 2 active trials by estimated primary completion.
| Est. completion | Trial | Sponsor | Phase | Participants |
|---|---|---|---|---|
| 2027-09-30 | RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) NCT07009860 · Relative (%) reduction in liver stiffness by VCTE compared to baseline | Altimmune, Inc. | P2 | 121 |
| 2028-12 | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH NCT07795164 · Clinical Outcome Event | Altimmune, Inc. | P3 | 1,800 |
Indications under study
Alcohol-associated Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH).